Liantuo Bio has introduced over 200 million US dollars!

On April 20, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that a new class 2.

Screenshot source: CDE official website

According to public information, Nanobiotix is ​​a late-stage clinical development biotechnology company dedicated to bringing new treatment options to patients through physical principles-based treatments

The physical mechanism of action of NBTXR3 is designed to be activated by radiotherapy, induce massive tumor cell death within the injected tumor, and subsequently trigger an adaptive immune response and long-term anticancer memory

In May 2021, LianBio announced a partnership with Nanobiotix to obtain an exclusive license to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore and Thailand

For the HNSCC indication, NBTXR3 has previously produced consistent safety data and early indications of efficacy in a Phase 1 dose escalation and dose expansion study

Head and neck squamous cell carcinoma is a heterogeneous malignancy

References:

[1] The official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China.